Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses
Open Access
- 4 August 2020
- Vol. 12 (8), 2153
- https://doi.org/10.3390/cancers12082153
Abstract
A significant number of meta-analyses reporting data on the diagnostic performance of positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature. In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review is to summarize information retrieved by published meta-analyses on this topic. The first step included a systematic search of the literature (last search date: June 2020), screening two databases (PubMed/MEDLINE and Cochrane Library). This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis. Only meta-analyses on Positron Emission Tomography/Computed Tomography (PET/CT) or Positron Emission Tomography/Magnetic Resonance (PET/MR) in PCa were selected. We have summarized the diagnostic performance of PET imaging in PCa, taking into account 39 meta-analyses published in the literature. Evidence-based data showed the good diagnostic performance of PET/CT with several radiopharmaceuticals, including prostate-specific membrane antigen (PSMA)-targeted agents, radiolabeled choline, fluciclovine, and fluoride in restaging and staging settings. Less evidence-based data were available for PET/MR with different radiotracers. More prospective multicentric studies and cost-effectiveness analyses are warranted.Keywords
This publication has 49 references indexed in Scilit:
- Discordance rate between radiolabelled choline PET/CT and bone scintigraphy in detecting bone metastases in patients with prostate cancer: a meta-analysisClinical and Translational Imaging, 2015
- Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysisSkeletal Radiology, 2014
- Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancerNuclear Medicine Communications, 2014
- Incidental uptake of 18F-fluorodeoxyglucose in the prostate glandNuklearmedizin-Nuclear Medicine, 2014
- Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysiscclm, 2013
- Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literatureBJU International, 2013
- Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysisEuropean Urology, 2013
- Choline PET or PET/CT and Biochemical Relapse of Prostate CancerClinical Nuclear Medicine, 2013
- The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2013
- Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-CholineJournal of Nuclear Medicine, 2010